Clinical Trials Browser

Completed × Fluorodeoxyglucose F18 × CNS × Clear all

NCT03732352 2024-11-12

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

Phase 2 Completed

Glioblastoma

NCT04219969 2024-05-09

FDG PET-MRI for the Diagnosis of Spinal Cord Lesions

Phase NA Completed

Spinal Cord Neoplasms

NCT05054998 2024-05-01

Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases

Phase 4 Completed

Brain Neoplasms, Neoplasm Metastasis

NCT00662506 2023-06-06

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Phase 1/2 Completed

Glioblastoma, Gliosarcoma

NCT00813566 2022-04-27

Multi-Tracer PET Assessment of Primary Brain Tumors

Phase 1 Completed

Brain Neoplasms, Neoplasms

NCT01806675 2019-10-03

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

Phase 1/2 Completed

25 enrolled 14 charts

BreastCNSGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Tongue Neoplasms, Esthesioneuroblastoma, Olfactory, Gliosarcoma, Breast Neoplasms, Male

NCT00381797 2017-11-28

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

Phase 2 Completed

97 enrolled 35 charts

Familial ependymoma, Medulloblastoma, Oligodendroglioma, Spinal Cord Neoplasms